-

Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis

Streamlined analysis of 40 PFAS compounds in wastewater and soil

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US) Environmental Protection Agency (EPA) Method 1633 (3rd draft). EPA Draft Method 1633 currently analyzes 40 PFAS compounds in wastewater and soil and is a complex and labor-intensive method, relying on multiple sample preparation and analysis steps. Success in running the technique depends on careful sample handling and the appropriate sample preparation supplies and instrumentation.

The new workflow synchronizes with the recent launch of the Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) system along with specific PFAS consumables, including the Agilent Bond Elut PFAS WAX Solid Phase Extraction (SPE) Cartridges, that provide the best recoveries while eliminating PFAS contamination and background, as well as the Agilent Infinity Lab PFC-free HPLC conversion kit, ‘PFAS-free’ Agilent vials and caps and other consumables. Specific data reporting needs for EPA 1633 are addressed through Agilent’s MassHunter Software, and sample tracking of the entire workflow can be done using the Agilent SLIMS Lab Management Platform enabling automation in data review and sample tracking which increases efficiency.

“PFAS are persistent, bioaccumulative, and of concern globally, with several countries looking to regulate them in water and soil. As a market leader in environmental analysis, Agilent is pleased to offer our customers a solution to achieve EPA Method 1633 performance requirements confidently,” explained Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division. “This new workflow simplifies setup and provides a robust end-to-end analytical methodology that reduces method development time, increases throughput and accuracy, allowing customers to focus on running critical samples.”

Agilent’s Bond Elut PFAS WAX SPE Cartridges are explicitly designed for PFAS analysis, providing excellent extraction performance and flow rates for a broad range of PFAS compounds while complying with stringent regulatory requirements. The cartridges undergo PFAS-specific QC testing to ensure optimal cleanliness and recovery, so customers can confidently isolate PFAS from environmental matrices, such as wastewater and soil.

SLIMS simplifies the intake of analytical requests and streamlines task management. Connected to the 6495 LC/TQ SLIMS guides users through the workflow and ensures the instrument, consumables, and reagents are fit for purpose. MassHunter software generates specific instrument data reports passing the information to SLIMS for evaluation of results and creation of the certificate of analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies, Inc.
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...
Back to Newsroom